# Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy

> **NCT01126866** · PHASE2 · TERMINATED · sponsor: **National Center for Tumor Diseases, Heidelberg** · enrollment: 35 (estimated)

## Conditions studied

- Colorectal Carcinoma

## Interventions

- **DRUG:** intensified chemotherapy (FOLFOXIRI/Bevacizumab)

## Key facts

- **NCT ID:** NCT01126866
- **Lead sponsor:** National Center for Tumor Diseases, Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06
- **Primary completion:** 2011-03
- **Final completion:** 2011-06
- **Target enrollment:** 35 (ESTIMATED)
- **Why stopped:** recruiting inadequate
- **Last updated:** 2011-07-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01126866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01126866, "Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01126866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*